SNCA and Parkinson disease: Furthermore, the development of next-generation PET tracers targeting amyloid plaques, tau, alpha-synuclein aggregates, and inflammatory markers has provided molecular insights into the pathological processes driving diseases like Alzheimer’s, Parkinson’s, and MS [29,30].